Cargando…
COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896421/ https://www.ncbi.nlm.nih.gov/pubmed/35319381 http://dx.doi.org/10.2174/1573403X18666220321105909 |
_version_ | 1784882047158845440 |
---|---|
author | Calcaterra, Giuseppe Bassareo, Pier Paolo De Gregorio, Cesare Barilla, Francesco Romeo, Francesco Mehta, Jawahar L. |
author_facet | Calcaterra, Giuseppe Bassareo, Pier Paolo De Gregorio, Cesare Barilla, Francesco Romeo, Francesco Mehta, Jawahar L. |
author_sort | Calcaterra, Giuseppe |
collection | PubMed |
description | In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigation and testing prior to gaining approval for use in practice. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, may be manifested following the administration of viral vector vaccines. It leads to severe clot formation at unusual sites approximately in 1 out of 110.000 vaccinated persons. This side effect, although rare, represents a newly devastating clotting phenomenon manifested in otherwise healthy young adults, who are often female. An in-depth description of the specific biological mechanisms implicated in the syndrome is here summarized. |
format | Online Article Text |
id | pubmed-9896421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-98964212023-11-02 COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art Calcaterra, Giuseppe Bassareo, Pier Paolo De Gregorio, Cesare Barilla, Francesco Romeo, Francesco Mehta, Jawahar L. Curr Cardiol Rev Cardiology In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigation and testing prior to gaining approval for use in practice. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, may be manifested following the administration of viral vector vaccines. It leads to severe clot formation at unusual sites approximately in 1 out of 110.000 vaccinated persons. This side effect, although rare, represents a newly devastating clotting phenomenon manifested in otherwise healthy young adults, who are often female. An in-depth description of the specific biological mechanisms implicated in the syndrome is here summarized. Bentham Science Publishers 2022-09-16 2022-09-16 /pmc/articles/PMC9896421/ /pubmed/35319381 http://dx.doi.org/10.2174/1573403X18666220321105909 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Cardiology Calcaterra, Giuseppe Bassareo, Pier Paolo De Gregorio, Cesare Barilla, Francesco Romeo, Francesco Mehta, Jawahar L. COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art |
title | COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art |
title_full | COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art |
title_fullStr | COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art |
title_full_unstemmed | COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art |
title_short | COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art |
title_sort | covid-19 vaccine-induced pro-thrombotic immune thrombocytopenia (vipit): state of the art |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896421/ https://www.ncbi.nlm.nih.gov/pubmed/35319381 http://dx.doi.org/10.2174/1573403X18666220321105909 |
work_keys_str_mv | AT calcaterragiuseppe covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart AT bassareopierpaolo covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart AT degregoriocesare covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart AT barillafrancesco covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart AT romeofrancesco covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart AT mehtajawaharl covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart |